XBIO vs. VYNE, FGEN, RLMD, NAII, DRRX, VVOS, BLRX, BIVI, LPCN, and MTEX
Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include VYNE Therapeutics (VYNE), FibroGen (FGEN), Relmada Therapeutics (RLMD), Natural Alternatives International (NAII), DURECT (DRRX), Vivos Therapeutics (VVOS), BioLineRx (BLRX), BioVie (BIVI), Lipocine (LPCN), and Mannatech (MTEX). These companies are all part of the "med - drugs" industry.
Xenetic Biosciences vs. Its Competitors
VYNE Therapeutics (NASDAQ:VYNE) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.
VYNE Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.
In the previous week, VYNE Therapeutics had 3 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for VYNE Therapeutics and 0 mentions for Xenetic Biosciences. VYNE Therapeutics' average media sentiment score of 1.04 beat Xenetic Biosciences' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the media.
VYNE Therapeutics presently has a consensus target price of $6.25, suggesting a potential upside of 384.50%. Given VYNE Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VYNE Therapeutics is more favorable than Xenetic Biosciences.
Xenetic Biosciences has higher revenue and earnings than VYNE Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Xenetic Biosciences has a net margin of -142.10% compared to VYNE Therapeutics' net margin of -6,974.55%. Xenetic Biosciences' return on equity of -57.31% beat VYNE Therapeutics' return on equity.
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 4.8% of VYNE Therapeutics shares are held by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
VYNE Therapeutics beats Xenetic Biosciences on 9 of the 16 factors compared between the two stocks.
Get Xenetic Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenetic Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:XBIO) was last updated on 7/8/2025 by MarketBeat.com Staff
Free XBIO Stock Alerts